Literature DB >> 15324701

Hepsin promotes prostate cancer progression and metastasis.

Olga Klezovitch1, John Chevillet, Janni Mirosevich, Richard L Roberts, Robert J Matusik, Valeri Vasioukhin.   

Abstract

The majority of cancer-related deaths are associated with metastasis; however, little is known about the mechanisms of this process. Hepsin is a cell surface serine protease that is markedly upregulated in human prostate cancer; however, the functional significance of this upregulation is unknown. We report here that hepsin overexpression in prostate epithelium in vivo causes disorganization of the basement membrane. Overexpression of hepsin in a mouse model of nonmetastasizing prostate cancer has no impact on cell proliferation, but causes disorganization of the basement membrane and promotes primary prostate cancer progression and metastasis to liver, lung, and bone. We provide in vivo evidence that upregulation of a cell surface serine protease in a primary tumor promotes cancer progression and metastasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15324701     DOI: 10.1016/j.ccr.2004.07.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  90 in total

1.  Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity.

Authors:  Johanna I Partanen; Topi A Tervonen; Mikko Myllynen; Essi Lind; Misa Imai; Pekka Katajisto; Gerrit J P Dijkgraaf; Panu E Kovanen; Tomi P Mäkelä; Zena Werb; Juha Klefström
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-20       Impact factor: 11.205

Review 2.  The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment.

Authors:  Toni M Antalis; Marguerite S Buzza; Kathryn M Hodge; John D Hooper; Sarah Netzel-Arnett
Journal:  Biochem J       Date:  2010-06-15       Impact factor: 3.857

3.  HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition.

Authors:  Ling Gao; Hongju Deng; Haibo Zhao; Angela Hirbe; John Harding; Lee Ratner; Katherine Weilbaecher
Journal:  Blood       Date:  2005-08-23       Impact factor: 22.113

Review 4.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

5.  Migrating with myosin VI.

Authors:  Beatrice Knudsen
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

6.  Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.

Authors:  Stephanie M Wittig-Blaich; Lukasz A Kacprzyk; Thorsten Eismann; Melanie Bewerunge-Hudler; Petra Kruse; Eva Winkler; Wolfgang S L Strauss; Raimund Hibst; Rudolf Steiner; Mark Schrader; Daniel Mertens; Holger Sültmann; Rainer Wittig
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

7.  A novel role of myosin VI in human prostate cancer.

Authors:  Thomas A Dunn; Shenglin Chen; Dennis A Faith; Jessica L Hicks; Elizabeth A Platz; Yidong Chen; Charles M Ewing; Jurga Sauvageot; William B Isaacs; Angelo M De Marzo; Jun Luo
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

8.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

Review 9.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

10.  Identification and characterization of small-molecule inhibitors of hepsin.

Authors:  John R Chevillet; Gemma J Park; Antonio Bedalov; Julian A Simon; Valeri I Vasioukhin
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.